<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02883803</url>
  </required_header>
  <id_info>
    <org_study_id>PHRCI 2012/CHOCMSC-GIBOT/SKJ</org_study_id>
    <nct_id>NCT02883803</nct_id>
  </id_info>
  <brief_title>Treatment of Severe Infections With Mesenchymal Stem Cells</brief_title>
  <acronym>CHOCMSC</acronym>
  <official_title>Effects of Mesenchymal Stem Cells Administration on Organ Failure During Septic Shock: Phase II Randomized Comprator-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose at the early phase of septic shock on the evolution of organ failure judged
      by the SOFA (Sepsis Organ Failure Assessment score) score on Day 7 (or the day of death or
      the day of discharge from the intensive care unit if before Day 7) compared to SOFA score
      observed in patients in the control group. The secondary purpose is to assess the role of
      heterologous mesenchymal stem cells on the occurrence and duration of failure of each organ
      and on the mortality at day 28 and day 90. The safety of administration will be also
      assessed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients hospitalized in recovery unit and having a very severe septic shock with community
      origin (≥ 2 organ failures other than hemodynamic) since less than 12 hours, will receive
      10^6/kg heterologous mesenchymal stem cells in 250 ml albumin 4%, infused for 30 minutes in
      central venous line or 250 ml albumin 4% alone.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2018</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SOFA score</measure>
    <time_frame>Day 7 (or death day or day of recovery unit exit if before day 7)</time_frame>
    <description>To assess the efficacy of a recovery treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of living days without catecholamines</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of living days without mechanical ventilation</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of living days without dialysis</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of residence time in recovery unit</measure>
    <time_frame>Day of exit from recovery unit, up to 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality, across all causes</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality, across all causes</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Administration safety (i.e. side effects)</measure>
    <time_frame>up to 90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>MSC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients hospitalized in recovery unit and having a very severe septic shock with community origin (≥ 2 organ failures other than hemodynamic) since less than 12 hours, will receive 10^6/kg heterologous mesenchymal stem cells in 250 ml albumin 4%, infused for 30 minutes in central venous line.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patients hospitalized in recovery unit and having a very severe septic shock with community origin (≥ 2 organ failures other than hemodynamic) since less than 12 hours, will receive 250 ml albumin 4%, infused for 30 minutes in central venous line.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Injection of mesenchymal stem cells</intervention_name>
    <description>Injection of mesenchymal stem cells</description>
    <arm_group_label>MSC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Injection of albumin alone</intervention_name>
    <description>Injection of albumin alone</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Septic shock of community origin since less than 12 hours. The onset time of septic
             shock is the time of catecholamine introduction( adrenaline, noradrenaline, or
             dopamine &gt; 8μg/kg/min)

          -  At least 2 organ failure other than hemodynamic

          -  Occurrence between Monday 8am and Friday 8am (for availability reasons of staff)

          -  Signature of informed consent (patient/close relative or reliable person)

          -  Affiliation to social security plan

        Exclusion Criteria:

          -  Non-septic shock

          -  Nosocomial septic shock

          -  PaO2/FiO2 &lt;100

          -  Pregnant or breast-feeding woman

          -  Brain death

          -  Dying person

          -  Therapeutic limitations

          -  Participation to another current interventional clinical trial or since less than 30
             days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sébastien GIBOT</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service de Réanimation Médicale, Hôpital Central, 54035, Nancy Cedex</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sébastien GIBOT</last_name>
    <phone>+33383852970</phone>
    <email>s.gibot@chu-nancy.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daniele BENSOUSSAN</last_name>
    <phone>+33383153779</phone>
    <email>d.bensoussan@chru-nancy.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service de Réanimation Médicale, Hôpital Bocage</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Pierre-Emmanuel Charles</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Réanimation Médicale, Hôpital Central</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Pierre Edouard Bollaert</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UTCT, Hôpital Brabois</name>
      <address>
        <city>Vandoeuvre-les-Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Danièle Bensoussan</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Véronique Decot</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2016</study_first_submitted>
  <study_first_submitted_qc>August 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2016</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

